Notes
The study was funded by GlaxoSmithKline.
Reference
Allen RA. Cost-Effectiveness of Eltrombopag versus Romiplostim for the Treatment of Chronic Immune Thrombocytopenia in England and Wales. Value in Health : 11 May 2016. Available from: URL: http://dx.doi.org/10.1016/j.jval.2016.03.1856
Rights and permissions
About this article
Cite this article
Eltrombopag "dominated" romiplostim for thrombocytopenia. PharmacoEcon Outcomes News 757, 13 (2016). https://doi.org/10.1007/s40274-016-3202-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-016-3202-2